BNTCBenitec Biopharma Inc.
Price
-46%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 5% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for BNTC today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. We are developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy ("OPMD"), a chronic, life-threatening genetic disorder.
In the company’s own words · 10-K filed Sep 14, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Dec 14, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study.Regulation FD disclosure · press release
- Sep 30, 2026New Independent Registered Public Accounting Firm As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP (“EY”) as the Company’s …Auditor change · Form 8-K
- Sep 24, 2026Baker Tilly US, LLP (“Baker Tilly”), the Company’s independent registered public accounting firm, has served as the Company’s auditor since 2020.Auditor change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.